Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy

Platonov, Pyotr G.; Haugaa, Kristina H.; Bundgaard, Henning; Svensson, Anneli; Gilljam, Thomas; Hansen, Jim; Madsen, Trine; Holst, Anders Gaarsdal; Carlson, Jonas; Lie, Øyvind H.; Kvistholm Jensen, Morten; Edvardsen, Thor; Jensen, Henrik K.; Svendsen, Jesper H.

Published in:
American Journal of Cardiology

DOI (link to publication from Publisher):
10.1016/j.amjcard.2018.12.049

Publication date:
2019

Document Version
Accepted author manuscript, peer reviewed version

Accepted Manuscript

Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy

Pyotr G Platonov MD PhD FHRS , Kristina H Haugaa MD PhD , Henning Bundgaard MD PhD , Anneli Svensson MD , Thomas Gilljam MD PhD , Jim Hansen MD PhD , Trine Madsen MD PhD , Anders Gaarsdal Holst MD PhD , Jonas Carlson MSc PhD , Øyvind H. Lie MD , Morten S Kvistholm Jensen MD , Thor Edvardsen MD PhD , Henrik K Jensen MD PhD , Jesper H Svendsen MD PhD

PII: S0002-9149(19)30056-6
DOI: https://doi.org/10.1016/j.amjcard.2018.12.049
Reference: AJC 23720

To appear in: *The American Journal of Cardiology*

Received date: 5 November 2018
Revised date: 19 December 2018

Please cite this article as: Pyotr G Platonov MD PhD FHRS , Kristina H Haugaa MD PhD , Henning Bundgaard MD PhD , Anneli Svensson MD , Thomas Gilljam MD PhD , Jim Hansen MD PhD , Trine Madsen MD PhD , Anders Gaarsdal Holst MD PhD , Jonas Carlson MSc PhD , Øyvind H. Lie MD , Morten S Kvistholm Jensen MD , Thor Edvardsen MD PhD , Henrik K Jensen MD PhD , Jesper H Svendsen MD PhD , Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy, *The American Journal of Cardiology* (2019), doi: https://doi.org/10.1016/j.amjcard.2018.12.049

Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy

Primary prevention ICD in ARVC

Pyotr G Platonov[a] MD PhD FHRS, Kristina H Haugaa[b] MD PhD, Henning Bundgaard[c] MD PhD, Anneli Svensson[d] MD, Thomas Gilljam[e] MD PhD, Jim Hansen[f] MD PhD, Trine Madsen[g] MD PhD, Anders Gaarsdal Holst[c] MD PhD, Jonas Carlson[a] MSc PhD, Øyvind H. Lie[b] MD, Morten S Kvistholm Jensen[h] MD, Thor Edvardsen[b] MD PhD, Henrik K Jensen[h,i] MD PhD, Jesper H Svendsen[c] MD PhD

a – Department of Cardiology, Clinical Sciences, Lund University
b - Center for cardiological innovation, Department of cardiology, Institute for surgical research, Oslo University Hospital, Rikshospitalet, Norway and Institute for clinical medicine, University of Oslo, Oslo, Norway
c – Department of Cardiology, The Heart Center, Rigshospitalet, University of Copenhagen, Denmark & Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
d – Department of Cardiology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
e – Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
f– Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
g – Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
h – Department of Cardiology, Aarhus University Hospital, Denmark
i - Department of Clinical Medicine, Health, Aarhus University, Denmark

Corresponding address:
Prof. Pyotr G Platonov
Department of Cardiology
Lund University, Lund 22185
Sweden
Tel: +46 46 172435
Fax: +46 46 157857
Pyotr.Platonov@med.lu.se

Nordic ARVC Registry received unrestricted grant from Medtronic Denmark

ABSTRACT

Implantable cardioverter-defibrillator (ICD) therapy remains a corner stone of sudden cardiac death (SCD) prevention in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). We aimed to assess predictors of appropriate ICD therapies in the Scandinavian cohort of ARVC patients who received ICD for primary prevention of SCD. Study group comprised of 79 definite ARVC patients by 2010 Task Force criteria (60% male, age at ICD implant 39±14 years) who were enrolled in the Nordic ARVC Registry and received an ICD for primary SCD prevention. The primary endpoint of appropriate ICD shock or death from any cause was assessed and compared with 137 definite ARVC patients who received ICD for secondary SCD prevention (74% male, age at ICD implant 42±15 years). In the study group, 38% were ≤35 years of age at baseline, 25% had non-sustained VT and 29% had syncope at baseline. Major repolarization abnormality (HR=4.00, 95%CI 1.30 – 12.30, p=0.015) and age ≤35 years (HR=4.21, 95%CI 1.49–11.85, p=0.001) independently predicted the primary endpoint. The outcome did not differ between the primary prevention patients with either of these risk factors and the secondary prevention cohort (2-4% annual event rate) while patients without risk factors did not have any appropriate ICD shocks during follow up. In conclusion, young age at ARVC diagnosis and major repolarization abnormality independently predict ICD shocks or death in the primary prevention ICD recipients and associated with the event rate similar to the one observed in the secondary prevention cohort. Our data indicate the benefit of ICD for primary prevention in patients with any of these risk factors.

KEY WORDS: arrhythmogenic right ventricular cardiomyopathy; implantable cardioverter-defibrillator; sudden cardiac death, prevention

INTRODUCTION

Increased awareness of arrhythmogenic right ventricular cardiomyopathy (ARVC) as a progressive inherited disease associated with the risk of sudden cardiac death (SCD) has lead to implementation of family screening strategies in clinical management guidelines[1] and revision of diagnostic criteria, which increased their sensitivity.[2] As a result, the number of ARVC patients requiring risk stratification regarding implantation of an implantable cardioverter-defibrillator (ICD) for primary prevention of SCD is growing. While secondary prevention ICD implantation in ARVC is based on a well-documented increased risk of life-threatening ventricular arrhythmias,[3-5] the literature regarding the primary prevention ICD indications is limited.[6, 7] We aimed to assess the predictors of ICD therapy in a large unselected cohort of patients with definite ARVC, who were diagnosed according to 2010 Task Force criteria (TFC2010) and received ICD implants for primary prevention of SCD, and compare the prognosis with secondary prevention ICD recipients, who represent an a priori high risk group in regard to ventricular arrhythmia recurrence. We also aimed to evaluate the risk factors associated with appropriate ICD therapies, identify patients at the highest risk of ventricular arrhythmias and describe subgroups of low risk patients, in whom ICD implantation for primary prevention may not be needed.

METHODS

The Nordic ARVC Registry (www.arvc.dk) was launched in June 2010 and includes patients diagnosed with definite ARVC by TFC2010 and followed through ICD outpatient clinics and dedicated cardio-genetics units affiliated with tertiary referral centers in Scandinavia.[8] We also prospectively recruit newly diagnosed patients. The register captured baseline clinical characteristics and the data specific for ARVC diagnostic criteria as proposed in the original Task Force recommendations from 1994[9] and the updated TFC2010.[2] Ventricular tachyarrhythmia data included in the registry are reported either as ECG-verified ventricular tachycardia or as captured by ICD device diagnostics. Historical information

regarding ventricular tachycardia (VT) prior to ARVC diagnosis or ICD implantation was retrieved from patients' medical records as assessed by a cardiology specialist.

Decision to implant ICD for primary prevention of SCD was guided by guideline documents, which were in force at the time when patients underwent clinical evaluation[10, 11] and local practice. Patients who received ICD after aborted cardiac arrest or documented sustained VT were considered secondary prevention ICD recipients while all other, including those with documented non-sustained VT, were considered as a primary prevention cohort. Secondary prevention ICD patients were used for comparison of clinical characteristics and clinical outcomes observed in the primary prevention group. Prospective follow-up information was available until November 2017. Regional ethics committees approved the study. In Denmark, the approval was obtained from the Danish Data Protection Agency. The study complies with the Declaration of Helsinki.

Continuous data are presented as mean ± standard deviation. Nominal data are presented as number (% of cases). Chi-squared or Fischer's exact test was used for comparison between categorical variables, and t-test was used for the comparison of continuous variables.

The primary study endpoint was appropriate ICD shock or death from any cause. The secondary study endpoint was any appropriate ICD therapy defined as either antitachycardia pacing (ATP) or shock or death from any cause. Subjects who did not have any appropriate ICD therapy were censored at the end of follow-up or heart transplantation. Kaplan–Meier product-limit method was used to generate a survival curve indicating time to endpoint from the ICD implantation date. Cox proportional hazard regression models were used to estimate the adjusted hazard ratios (HR) and their 95% confidence intervals (CI). Cox regression analyses were performed on the primary prevention cohort while the Kaplan Meier curves representing the outcome in the secondary prevention cohort were included for comparison of cumulative incidence of ICD therapies with the *a priori* high risk ARVC patients.

Univariable Cox regression analyses were performed for each component of TFC2010,

including imaging and ECG characteristics, gender, age, and history of syncope or VT prior to ICD implantation. The impact of age was assessed as a continuous variable and dichotomized using 35 years as a threshold as earlier proposed.[6] Since the proband status, which in previous studies was reported a predictor of arrhythmic events in ARVC,[7] indicates the first individual in a family from whom cascade screening is initiated, the proband status *per se* may not necessarily be related to the presence of phenotypical characteristics of the disease. Therefore it was substituted by the `Definite ARVC by phenotype´ status defined as individuals who fulfill TFC2010 for definite ARVC diagnosis without accounting for the family history or mutation carrying status. Multivariable analysis was performed only individual phenotypical characteristics of the disease, which demonstrated p-value <0.15 in the univariable analysis thus excluding composite disease characteristics such as proband status and the Definite ARVC by phenotype status. Multivariable analysis included a stepwise backward elimination using logistic regression. A two-sided P-value of 0.05 was considered statistically significant.

RESULTS

Of the total number of 296 patients with definite ARVC recruited by November 2017, 216 had an ICD implanted. ICD was implanted for secondary prevention of SCD in 137 patients while 79 patients constituted the primary prevention cohort (Table 1). One third of the study population was recruited prospectively with newly diagnosed ARVC after June 2010: 45 (33%) in the secondary and 23 (29%) in the primary prevention group.

Left ventricular (LV) involvement defined as reduced LV ejection fraction ≤40% was uncommon. A large proportion of patients underwent cardiac magnetic resonance imaging (CMR) in addition to a conventional echocardiography, which was performed in all subjects. Few patients underwent myocardial biopsy, which was performed on the RV free wall in only 9 subjects (4.2%) and on the RV septum in 59 (27%).

Genetic evaluation was performed in more than 80% of probands from both the secondary and primary prevention groups and in nearly half of the tested individuals it yielded positive

identification of a disease-causing genetic variant (n=93, 52%). The vast majority of mutation-positive probands carried a mutation in the plakophillin-2 (PKP2) gene (63%), followed by desmoglein-2 (DSG2, 18%), desmoplakin (DSP, 14%), DSC-2 (5.3%), TMEM43 (3.2%). Four patients had mutations identified in 2 desmosomal genes.

Primary asymptomatic patients, i.e. those who were diagnosed through cascade family screening and did not have any symptoms or documented ventricular arrhythmias prior to diagnosis constituted one third of the primary prevention cohort (n=25, 30%).

During a median follow-up of 89 [IQR 58 - 146] months after ICD implantation, 22 patients underwent heart transplantation and five died. One death occurred in the primary prevention group (cause unknown) and 4 in the secondary prevention group (2 non-cardiac, 1 within a month after heart transplantation and 1 unknown).

By the end of follow-up, 81 patients had experienced appropriate shocks (18 [23%] in the primary prevention and 63 [46%] in the secondary prevention group, p=0.002), while 147 experienced either appropriate shocks or ATP (46 [58%] in the primary prevention and 107 [78%] in the secondary prevention group, p=0.004). Out of 24 primary asymptomatic patients, 13 had ATP during follow-up and none experienced ICD shock. Inappropriate ICD shocks were seen in 24 patients and occurred with similar 10-year cumulative incidence among patients from primary vs secondary prevention cohort (15% vs 11%, p=0.839).

Results of univariable Cox regression analyses performed for the disease manifestations and diagnostic work up data are presented in Supplemental Table 1. The proband status, definite ARVC by phenotype status, young age (≤35 years), the major repolarization and the major depolarization criteria were significantly associated with primary endpoint in the univariable analysis. RV ejection fraction demonstrated a borderline significant inverse association with the primary outcome in the univariate analysis but was available only for the subset of patients who underwent CMR and therefore not included in the multivariate analysis. Proband status and definite ARVC by phenotype status, being composite characteristics of the

disease phenotype, were not included in the multivariable model together with individual phenotypical features of the disease.

Young age (≤35 years), major repolarization criterion, major depolarization criterion and the history of syncope entered the multivariable model that was also adjusted for gender. After stepwise backward elimination process using logistic regression, the age ≤35 and the presence of major repolarization criterion were included in the final model and appeared to be independent predictors of appropriate ICD shocks. For the secondary endpoint, only the major repolarization criterion remained the independent predictor of the outcome in the multivariable analysis (Table 2).

Figure 1 presents the outcome among the primary prevention cohort grouped by the presence of the risk factors identified in the multivariate analysis (age ≤ 35 years, major repolarization criterion). The presence of 2 risk factors was associated with the cumulative risk of events similar to the one demonstrated by the secondary prevention cohort while primary prevention patients who did not have either of the risk factors did not experience any appropriate ICD shock. C-statistics for the risk factor model was 0.80 (95%CI 0.69-0.89) for the primary and 0.62 (95%CI 0.50-0.75) for the secondary endpoints.

Cumulative risk of the study endpoints in the primary prevention group categorized by the presence of distinct disease phenotype, i.e. fulfillment of the definite ARVC diagnosis based on the phenotypical characteristics of the disease only and not requiring criteria from the family history or genetics, is presented in Figure 2. Primary prevention ICD carriers had cumulative incidence of appropriate ICD therapies in the same range as the secondary prevention cohort. On the other hand, the incidence of appropriate ICD shocks in patients without either of the risk factors or not fulfilling definite ARVC diagnosis without family history/genetic information was low and corresponded to the annual rate of 0-0.7% (Supplemental Table 2).

DISCUSSION

Our findings are based on the Scandinavian cohort of patients with definite ARVC who

received ICD implants for primary or secondary prevention of SCD. Two risk factors, young age and major repolarization criterion by ECG, each independently predicted appropriate ICD shocks or death among patients who received ICD for primary prevention of SCD. The cumulative incidence of appropriate ICD therapies in the primary prevention patients who had either of these two risk factors was similar to the one observed in the secondary prevention cohort. Patients with ARVC phenotype becoming apparent after 35 years of age who do not manifest with major repolarization abnormality or require family history/genetic criterion in order to fulfill definite ARVC diagnosis constitute a low risk group in regard to arrhythmic complications of the disease and may not require primary prevention ICD implantation.

Clinical characteristics of primary prevention ICD recipients demonstrate significant variability in the literature, which may affect the results of analyses yielding different clinical characteristics as independent predictors of arrhythmic outcomes. Our patients can be compared with two earlier reported primary prevention cohorts[6, 7] and the most recent report from the North American multidisciplinary study of ARVC, which included 56 patients who received ICD for primary prevention indication[12] (Table 3).

Similarly to the Johns Hopkins cohort,[7] our patients were diagnosed by TFC2010 and therefore also included patients with less severe disease manifestations. The prevalence of a history of syncope in our group was also remarkably similar to others.[7, 12] While being similar in regard to the ECG phenotype, our patients were older at ICD implantation, more often were men, and had less family members enrolled in the study than reported by Bhonsale et al.[7] The proportion of family members, who commonly demonstrate mild disease phenotype and low risk of arrhythmic complications of the disease, which may affect risk estimations, was strikingly similar in our and Johns Hopkins cohort.[7] The rate of ICD interventions, such as cumulative incidence of any appropriate ICD therapy by 10 years of follow-up is also similar to earlier reported being 63% in the Johns Hopkins cohort compared to 67% in ours.

While syncope is a recognized risk factor in patients with ARVC and is listed as a class

IIb indication[11] for ICD implantation, the data supporting this recommendation came mostly from the study on patients diagnosed by TFC1994[6] while contemporary primary prevention studies[7,12] did not support syncope as an independent predictor of appropriate ICD therapy. Our findings of the syncope lacking any predictive value for appropriate ICD therapies are therefore in accord with earlier findings in the primary prevention settings.

Previously published data in support of NSVT as a risk marker give a mixed picture. Although most of studies report NSVT as a predictor of appropriate ICD therapies un univariate analyses,[4, 6, 13] this was not supported by all[14] and only one earlier study devoted to the primary prevention found it to be an independent predictor of appropriate ICD therapies.[7] In our cohort, the prevalence of NSVT prior to ICD implantation is much lower than the one reported in the Johns Hopkins cohort.[7] Additional studies are therefore needed to resolve the uncertainty regarding predictive value of NSVT as a SCD risk indicator.

It has been observed that arrhythmic manifestations of ARVC are linked to other phenotypic characteristics of the disease[15] and its progression to the overt phenotype, which can be assessed as the age of ARVC diagnosis. Earlier data have consistently reported that younger age at diagnosis was associated with VT during follow-up.[6, 7, 12, 13] Our findings are in line with these previous observations and support the use of age at disease presentation as a risk marker of arrhythmic events during follow-up. Though the age at ICD implantation was included in the multivariable analysis as the time point for the start of follow-up in order to capture the study endpoints defined as appropriate ICD therapies or death, the mean difference between the age at diagnosis and the age at ICD implantation was less than one year and was not different between the groups.

Our data suggest that early disease manifestation or T-wave inversion meeting criteria for major repolarization criteria are associated with 4-fold increased risk of appropriate ICD shocks or death. Cumulative incidence of ICD therapies in high-risk patients from the primary prevention cohort was also found to be very similar to the incidence observed among the

secondary prevention cohort. This further illustrates the primary prevention risk stratification challenge as, based on our findings, patients with early disease manifestations may be expected to received ICD therapies to the same extent as secondary prevention ARVC patients.

Among the diagnostic criteria, which constitute the disease phenotype, ECG characteristics that reflect depolarization and repolarization abnormalities meeting definitions for major criteria appeared to be univariate predictors of the primary endpoint, of which abnormal ventricular repolarization consistent with the major diagnostic criterion appeared to be the strongest predictor while arrhythmic criteria were not significantly associated with the outcome.

While the use of ICD therapies and inclusion of ATP in the secondary endpoint may overestimate the life-saving efficacy of ICD therapy, the lack of ICD therapies can be used for identification of patients who would not benefit from ICD implantation. Our data further support earlier observations that family members, and primary asymptomatic family members in particular, are at low risk of arrhythmic events.[7, 16] In our study, primary asymptomatic patients did not have any appropriate ICD shocks during follow-up.

Our cohort consists of patients who were under clinical follow-up by the register launch in June 2010 and those who were prospectively enrolled with newly diagnosed ARVC since then, which is a limitation of the study. However, the main endpoint of the study, i.e. delivery of ICD therapies, is governed by strict documentation requirements in the participating countries, which supports the validity of the study endpoint. We have not been able to distinguish delivery of ICD therapies dependent on the cycle length of VT/VF in our study and thus could not reliably distinguish whether ICD shocks were delivered for fast or slow VT. The rate of therapy delivery, however, appears to be in the same range as the one reported in an earlier contemporary long-term follow-up primary prevention ARVC population,[7] which supports clinical validity of our study findings. Finally, despite being a relatively large study in the context of ARVC, the size of our cohort is still not sufficient for definitive conclusions

concerning other risk factors, which have not demonstrated predictive value in our study.

In conclusion, our data based on a contemporary cohort of patients with definite ARVC diagnosed using TFC2010 treated with ICD for primary prevention of SCD further supports the use of severe disease phenotype, young age at ARVC diagnosis, and electrocardiographic ventricular repolarization abnormalities in particular, as the major risk factors predicting appropriate ICD therapies. Family history of SCD at young age in a first degree relative was not associated with increased risk of ventricular arrhythmic events in primary prevention ICD recipients.

ACKNOWLEDGEMENTS

Medtronic Denmark supported the establishment of the Nordic ARVC registry by an unrestricted research grant. Dr Platonov was supported by The Swedish Heart-Lung Foundation (grant #20150574), governmental funding within the Swedish health care service and donation funds at Skåne university hospital. Dr Henrik K. Jensen is supported by the Novo Nordisk Foundation (NNF18OC0031258).

1. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G and Tracy C. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. *Heart Rhythm* 2013;10:1932-1963.
2. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T and Zareba W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. *Circulation* 2010;121:1533-1541.

3. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA, 3rd, Buja G and Thiene G. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Circulation* 2003;108:3084-3091.
4. Roguin A, Bomma CS, Nasir K, Tandri H, Tichnell C, James C, Rutberg J, Crosson J, Spevak PJ, Berger RD, Halperin HR and Calkins H. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *J Am Coll Cardiol* 2004;43:1843-1852.
5. Wichter T, Paul M, Wollmann C, Acil T, Gerdes P, Ashraf O, Tjan TD, Soeparwata R, Block M, Borggrefe M, Scheld HH, Breithardt G and Bocker D. Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. *Circulation* 2004;109:1503-1508.
6. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes NA, 3rd, Wichter T, McKenna WJ, Thiene G and Marcus FI. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. *Circulation* 2010;122:1144-1152.
7. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D, Tedford R, Russell SD, Abraham T, Tandri H, Judge DP and Calkins H. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-

defibrillator implantation for primary prevention. *J Am Coll Cardiol* 2011;58:1485-1496.

8. Borgquist R, Haugaa KH, Gilljam T, Bundgaard H, Hansen J, Eschen O, Jensen HK, Holst AG, Edvardsen T, Svendsen JH and Platonov PG. The diagnostic performance of imaging methods in ARVC using the 2010 Task Force criteria. *Eur Heart J Cardiovasc Imaging* 2014;15:1219-1225.
9. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G and Camerini F. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Br Heart J* 1994;71:215-218.
10. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Blanc JJ, Budaj A, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, Smith SC, Jr., Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. *Eur Heart J* 2006;27:2099-2140.
11. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C and Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). *Eur Heart J* 2015;36:2793-2867.

12. Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, Marcus F and Estes NA, 3rd. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. *J Am Coll Cardiol* 2014;64:119-125.
13. Piccini JP, Dalal D, Roguin A, Bomma C, Cheng A, Prakasa K, Dong J, Tichnell C, James C, Russell S, Crosson J, Berger RD, Marine JE, Tomaselli G and Calkins H. Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. *Heart Rhythm* 2005;2:1188-1194.
14. Lemola K, Brunckhorst C, Helfenstein U, Oechslin E, Jenni R and Duru F. Predictors of adverse outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: long term experience of a tertiary care centre. *Heart* 2005;91:1167-1172.
15. Zorzi A, Rigato I, Pilichou K, Perazzolo Marra M, Migliore F, Mazzotti E, Gregori D, Thiene G, Daliento L, Iliceto S, Rampazzo A, Basso C, Bauce B and Corrado D. Phenotypic expression is a prerequisite for malignant arrhythmic events and sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy. *Europace* 2016;18:1086-1094.
16. Peters S. Long-term follow-up and risk assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy: personal experience from different primary and tertiary centres. *J Cardiovasc Med*. 2007;8:521-526.

FIGURE LEGENDS





Figure 1. Kaplan Meier curve analysis of the risk of the primary (A) or secondary (B) endpoints in patients with ascertained ARVC diagnosis. Primary prevention cohort is presented as 4 groups (1A-1D) based on the presence of the disease characteristics identified in a multivariate analysis as independent predictors of appropriate ICD shocks or death from any cause: age at ARVC diagnosis ≤35 years and major repolarization criterion. Kaplan-Meier curves representing the risk of ICD therapies in the secondary prevention cohort is presented for comparison.





Figure 2. Kaplan Meier curve analyses of the risk of the primary (A) and secondary (B) endpoints in patients with ascertained ARVC diagnosis. Primary prevention cohort is presented as 4 groups (1A-1D) based on the age of diagnosis and the presence of definite ARVC diagnosis by TF2010, not requiring diagnostic criteria from the family history/genetic category. Kaplan-Meier curves representing the risk of ICD therapies in the secondary prevention cohort is presented for comparison.

Table 1. Clinical characteristics of patients with definite ARVC (TF2010) who received ICD for primary and secondary prevention of SCD in the Nordic ARVC Registry

	Secondary prevention n=137	**Primary prevention** n=79	**P-value**
	1	**2**	
Men	**101(74%)**	**47 (60%)**	**0.022**
Probands	**128 (93)**	**51 (65)**	**<0.001**
Definite ARVC by TFC2010 criteria without Family history/Genetics	**122 (89)**	**53 (67)**	**<0.001**
Age at ICD implantation (years)	42±15	39±14	0.154
Age at diagnosis (years)	41±16	38±14	0.093
Age ≤35 years at ICD implantation, n (%)	47 (34)	30 (38)	0.345
SCD in a 1st degree relative <35 years	**8 (6)**	**11(15)**	**0.038**
Competitive athlete	**57 (42%)**	**15 (19%)**	**<0.001**
VT prior to ICD implantation[a]	**111 (81%)**	**20 (25%)**	**<0.001**
Syncope prior to ICD implantation	**25 (18%)**	**23 (29%)**	**0.048**
Imaging criterion, major	**108 (79%)**	**53 (67%)**	**0.041**
Imaging criterion, minor	113 (83%)	57 (72%)	0.054
LVEF (%)	56±8	53±12	0.308
LVEF ≤40%	9 (6.6%)	8 (10%)	0.248
Cardiac CMR performed	97 (71%)	40 (50%)	
RVEF by CMR (%)	39±9	41±14	0.367
RVEDV/BSA by CMR (ml/m^2)	**129±32**	**118±52**	**0.009**
LGE-positive	33 (44%)	10 (25%)	0.321
Tissue criterion major	5 (3.6%)	3 (4%)	0.612
Tissue criterion minor	0	0	N/A
Repolarization criterion major	73(53%)	39 (49%)	0.339
Repolarization criterion minor	87 (64%)	47 (61%)	0.398
Depolarization criterion major	13 (9.5%)	6 (7.6%)	0.419
Depolarization criterion minor	**92 (67%)**	**36 (46%)**	**0.002**
T-wave inversion inferior	41 (30%)	18 (23%)	0.165
Arrhythmia criterion major	61 (45%)	13 (17%)	<0.001
Arrhythmia criterion minor	123 (89%)	71 (90%)	0.590
Family history criterion major	**78 (57%)**	**58 (73%)**	**0.011**
Family history criterion minor	**1 (0.7%)**	**8 (10%)**	**0.002**
Genetic evaluation performed in probands	104 (81%)	42 (82%)	1.000
Desmosomal mutations in probands	**68 (53%)**	**25 (49%)**	**0.024**

a) – For the primary prevention group, VT history concerns history of non-sustained VT.

ARVC – arrhythmogenic right ventricular cardiomyopathy; BSA – body surface area; CMR – cardiac magnetic resonance imaging; ICD – implantable cardioverter-defibrillator; LGE – late gadolinium enhancement; LVEF – left ventricular ejection fraction; RVEDV – right ventricular end-diastolic volume; RVEF – right ventricular ejection fraction; TFC – Task Force criteria; SCD – sudden cardiac death; VT – ventricular tachycardia

Table 2: Results of the multivariable analysis of appropriate ICD therapy predictors in the primary prevention ARVC cohort. Age <35 years, major repolarization abnormality, major depolarization abnormality and the history of syncope were included in the multivariable model that was adjusted for gender.

	Multivariable Cox regression			
	HR	**95% Confidence interval**		**p-value**
Any appropriate ICD shock or death from any cause				
Age < 35 years	4.21	1.49	11.85	0.006
Major repolarization abnormality	4.00	1.30	12.30	0.015
Any appropriate ICD shock or ATP or death from any cause				
Major repolarization abnormality	2.32	1.22	4.43	0.010

ARVC – arrhythmogenic right ventricular cardiomyopathy; ATP – antitachycardia pacing; HR – hazard ratio; ICD – implantable cardioverter-defibrillator;

Table 3. Clinical characteristics of ARVC patients with definite diagnostic category by TFC2010 from contemporary primary prevention cohorts.

	Bhonsale 2011[7]	**Link 2014[12]**	**Nordic ARVC Registry**
Variable	n=84*	n=56	n=79
Age (years)	32±12	40±14	39±14
Male gender	46%	60%	60%
Mean follow-up duration (months)	57	29	89
History of syncope	27%	25%	29%
History of NSVT	49%	16%	25%
Family History of SCD	17%	17%‡	15%
Right precordial T-wave inversion (V_1-V_3)	68%	76%	49%
Major RV abnormality	29%	71%‡	67%
LVEF <55%	25%	13%‡	24%

* - Only 70 of 84 patients fulfilled criteria for definite ARVC. ‡ - data not published, provided by North American multidisciplinary ARVC study team. ARVC – arrhythmogenic right ventricular cardiomyopathy; LVEF – left ventricular ejection fraction; NSVT – non-sustained ventricular tachycardia; SCD – sudden cardiac death.